BLB(SZ:002286)2025-04-24 13:25Financial Performance - The company's operating revenue for 2024 was ¥2,401,754,836.26, a decrease of 4.84% compared to ¥2,523,914,007.74 in 2023[22]. - Net profit attributable to shareholders for 2024 was ¥111,159,811.78, representing a significant increase of 105.97% from ¥53,969,019.70 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥123,895,301.04, up 254.56% from ¥34,943,020.97 in 2023[22]. - The company's cash flow from operating activities for 2024 was ¥248,722,360.34, down 11.89% from ¥282,283,397.63 in 2023[22]. - Basic and diluted earnings per share for 2024 were both ¥0.30, a 100% increase from ¥0.15 in 2023[22]. - Total assets at the end of 2024 were ¥2,673,967,499.20, a slight increase of 0.57% from ¥2,658,892,343.60 at the end of 2023[22]. - The net assets attributable to shareholders at the end of 2024 were ¥2,041,529,687.09, up 2.93% from ¥1,983,485,817.04 at the end of 2023[22]. Dividend and Shareholder Engagement - The company plans to distribute a cash dividend of 0.6 RMB per 10 shares (including tax) to all shareholders[5]. - The financial report ensures the accuracy and completeness of the financial statements, with all board members present for the meeting[5]. - The company has a clear commitment to maintaining transparency and accountability in its financial reporting[5]. - The board secretary and securities representative can be contacted at the same address and phone number[18]. - The company actively engages with shareholders and ensures equal treatment, providing timely disclosures and facilitating participation in shareholder meetings[200]. Market and Industry Trends - The global market for prebiotics is expanding as consumer awareness of dietary supplements and health foods increases, with significant growth observed in developed countries since the 1970s[40]. - The market for prebiotics is expected to grow significantly, driven by increasing demand in health supplements, dairy, and infant formula sectors[40]. - The global market size for probiotic-containing consumer products reached $8.628 billion in 2023, with the food and beverage segment accounting for 71% of this market[41]. - The global oligosaccharide market is projected to reach $1.386 billion in 2024, with a compound annual growth rate (CAGR) of 3.9%, expected to grow to $1.806 billion by 2031[42]. - The competitive landscape of the prebiotic industry is characterized by high entry barriers due to the need for long-term technological accumulation and proprietary technology protection by leading firms[42]. - The company anticipates growth opportunities driven by rising health-conscious consumer trends and an aging population[180]. Product Development and Innovation - The company plans to launch new products in 2024, including 2'-FL and LNnT from human milk oligosaccharides, and start production of isomerized lactose[45]. - The company is enhancing its product portfolio with precision prebiotics that promote beneficial bacteria growth and improve product stability[45]. - The company has developed over 90 different specifications of functional food ingredient products, making it one of the manufacturers with the most comprehensive product specifications in the global industry[93]. - The company is focused on expanding its product range with new developments such as DHA products and lactose-derived products, targeting diverse market needs[154]. - The company has initiated a 20,000-ton expansion project for allulose, aiming to replace a portion of the sugar market[103]. Research and Development - The company has a strong focus on R&D, collaborating with top universities and research institutions to drive innovation in health and nutrition[115]. - R&D investment amounted to ¥98,096,099.94 in 2024, reflecting a 1.14% increase from ¥96,985,747.36 in 2023[157]. - The proportion of R&D investment to operating revenue rose to 4.08% in 2024, up from 3.84% in 2023, an increase of 0.24%[157]. - The company completed the development of high-yield DPE enzyme strains for D-allohexose production, aiming to meet both domestic and international market demands[153]. - The company is committed to continuous R&D investment, utilizing synthetic biology and fine fermentation technologies to enhance product competitiveness[126]. Supply Chain and Production - The company operates a comprehensive supply chain from raw materials to end products, enhancing its competitive advantage through vertical and horizontal integration[112]. - The company has optimized its supply chain and production processes, leading to a reduction in procurement costs and production costs, enhancing overall profitability[123]. - The company employs a market-oriented production model, focusing on flexible production to meet high-value orders and improve product structure[110]. - The company recognizes the risk of demand fluctuations from downstream clients in the functional food and beverage sectors and plans to explore new application areas and develop new downstream clients[187]. Regulatory and Compliance - The company has received multiple international certifications, including GRAS and organic food certifications, demonstrating its commitment to product quality and compliance[83]. - The implementation of new national food safety standards in 2024 will boost the demand for natural sweeteners and functional health foods like prebiotics and dietary fibers[85]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency and accountability in its operations[197]. Financial Management - The company engaged in hedging activities to mitigate market risks associated with raw material price fluctuations[173]. - The total initial investment in derivative products was 3,820.99 million yuan, with a fair value change of -794.23 million yuan during the reporting period[172]. - The company plans to focus on high-value-added and flexible business models over the next 3-5 years, aiming to expand its market share in the food nutrition sector[181]. - The company aims to optimize its product structure by increasing the market share of high-margin products such as prebiotics and dietary fibers[182].